Terms: = Lung cancer AND MED12, Q93074, TRAP230, TNRC11, OKS, KIAA0192, HOPA, FGS1, CAGH45, ARC240, 9968 AND Treatment
5 results:
1. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
Kondo N; Utsumi T; Shimizu Y; Takemoto A; Oh-Hara T; Uchibori K; Subat-Motoshi S; Ninomiya H; Takeuchi K; Nishio M; Miyazaki Y; Katayama R
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917191
[TBL] [Abstract] [Full Text] [Related]
2. Association of clinico-genomic characteristics with tumor mutational burden in small cell lung cancer patients.
Kachroo S; Shao C; Desai K; He J; Jin F; Sen S
Future Oncol; 2021 Feb; 17(4):423-433. PubMed ID: 33198513
[No Abstract] [Full Text] [Related]
3. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathologic Features and Genetic Alterations of a Primary Osteosarcoma of the Uterine Corpus.
Zheng G; Richmond A; Liu C; Berrebi A; Pallavajjala A; Haley L; Stone RL; McCarthy E; Vang R; Xing D
Int J Gynecol Pathol; 2019 Sep; 38(5):414-419. PubMed ID: 29629977
[TBL] [Abstract] [Full Text] [Related]
5. Genetics and biomarkers in personalisation of lung cancer treatment.
Rosell R; Bivona TG; Karachaliou N
Lancet; 2013 Aug; 382(9893):720-31. PubMed ID: 23972815
[TBL] [Abstract] [Full Text] [Related]
